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We read with interest the study by Fazekas and colleagues demonstrating that lower levels of carboxyhemoglobin are associated with increased mortality in critically ill patients \[[@B1]\]. This observation is of interest since prior studies have shown that carbon monoxide (CO), the silent killer, may actually have therapeutic applications. CO suppresses inflammation and apoptosis, reduces pulmonary hypertension and potentially protects against multiple organ injury in animal models \[[@B2]\]. The fact that average carboxyhemoglobin levels are slightly lower in ICU nonsurvivors compared with survivors (1.5% vs. 1.6%, *P*= 0.003) supports the findings of animal studies.

However, an important confounding factor deserves consideration. ICU nonsurvivors are sicker and therefore likely to receive a higher FiO~2~than ICU survivors. Most hospitals supply oxygen from liquid oxygen, whereas medical air is supplied by compressing filtered environ-mental air. Previous work at Pittsburgh has shown that nitric oxide (NO) contamination of compression medical air resulted in a clinically detectable difference in NO levels that directly altered oxygenation \[[@B3]\]. The air in most major cities is also contaminated with CO \[[@B4]\] consequent to fossil fuel combustion. Medical air thus contains varying amounts of CO, as well as other pollutants. Patients receiving a higher FiO~2~receive less medical air, and are therefore exposed to less occult CO. This reduction in medical air might explain the small differences in carboxyhemoglobin seen in the present study, just as it explained the lower NO levels. Until this confounding influence is accounted for, the prior observations may merely reflect this CO washout phenomenon.
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We kindly thank Cove and Pinsky for their reply to our study. Based on the CO content of medical air and oxygen, they provide a potential explanation for the observed differences in carboxyhemoglobin levels in ICU survivors and nonsurvivors described in our study. We regret that the absence of data on the FiO~2~fractions used in our study population does not enable us to further test the relation between the amount of oxygen used and carboxyhemoglobin levels.

Sheu and colleagues found an increased activity of the heme oxygenase-1 gene to be associated with a reduced risk for the development of adult respiratory distress syndrome \[[@B5]\]. This finding leads us to assume that there is - at least in part - a genetic basis to the differences in carboxyhemoglobin levels and mortality. Furthermore, Melley and colleagues found elevated maximum carboxyhemoglobin levels to be associated with an increased mortality in critically ill patients following cardiothoracic surgery \[[@B6]\] - which would potentially argue against the hypothesis by Cove and Pinsky. Of note, however, this finding was not reproduced in our study.
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